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BACKGROUND: The introduction of mechanism-based targeted therapies to treat human cancers has been pledge as one of the results of three decades 
of remarkable progress of research into the mechanisms 
of cancer pathogenesis. We ponder how the description 
of hallmark principles is start to inform therapeutic 
development currently and may increasingly do so in the 
future.
CONTENT: There are 10 biological capabilities involved 
as the hallmarks of cancer, during the multistep of human 
tumors development. These hallmarks simplify the 
complexities of neoplastic disease into a structured rational 
principles, includes sustaining proliferative signaling, 
Abstract
R E V I E W  A R T I C L E
eluding growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating 
invasion and metastasis, genome instability, inflammation, 
reprogramming  energy metabolism and evading immune 
destruction.  
SUMMARY: The 10 hallmarks of cancer, in other words, 
the tumor’s distinctive and complementary capabilities that 
enable its growth and metastatic dissemination, continue 
to provide a solid foundation for understanding the 
biology of cancer. The ackowledgement of the widespread 
applicability of these concepts will increasingly influence 
the development of new manners to treat human cancer.
KEYWORDS: hallmark of cancer, cancer genome, 
inflammation, cancer immunology, metastasis
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Introduction
Hanahan and Weinberg have suggested that 6 hallmarks 
of cancer together form an organizing principle that offers 
a logical framework for understanding the remarkable 
diversity of neoplastic diseases. As normal cells evolve 
progressively to a neoplastic state, they obtain a succession 
of these hallmark abilities, and that the multistep process of 
human tumor pathogenesis could be rationalized by the need 
of incipient cancer cells to obtain the traits which enable 
them to become tumorigenic and ultimately malignant.(1) 
Tumors are not merely insular masses of proliferating cancer 
cells. Instead, they are complex tissues composed of multiple 
distinct cell types that engage in heterotypic interactions 
with one another. Normal cells recruited can form tumor-
associated stroma and shift the cells not again as a passive 
bystanders but actively participated in tumorigenesis, as 
such, the stromal cells formed also involved in certain 
hallmark capabilities development and expression. The 
biology of tumors can no longer be understood only by 
enumerating the traits of cancer cells, yet must encompass 
the contributions of the ‘‘tumor microenvironment’’ to 
tumorigenesis instead.(1)
 Over the last 10 years, the genomic landscapes of 
common forms of human cancer  have been revealed thanks 
to the comprehensive sequencing attempts. For most cancer 
types, this landscape consists of a few number of  “mountains” 
(genes changed in a great percentage of tumors) and a much 
larger number of “hills” (genes changed infrequently). Up 
54
The Indonesian Biomedical Journal, Vol.9, No.2, August 2017, p.53-72 Print ISSN: 2085-3297, Online ISSN: 2355-9179
to now, these studies have revealed about 140 genes that, 
when changed by intragenic mutations, can encourage or 
“drive” tumorigenesis. A typical tumor contains 2 to 8 of 
these “driver gene” mutations, the remaining mutations are 
passengers which give no selective growth benefit. Driver 
genes can be classified into 12 signaling pathways that 
regulate three core cellular processes, which are cell fate, cell 
survival and genome maintenance. A better understanding 
of these pathways is one of the most importunate needs in 
basic cancer research. Even at the moment, our knowing 
of cancer genomes is enough to guide the development of 
way effective approaches for reducing cancer morbidity and 
mortality.(2) The results of these attempts and the rigor with 
which they are implemented will determine whether and 
how comprehensive tumor genomic information may be 
incorporated into the routine care of patients with cancer.(3)
 Because of the definitive role of inflammatory 
responses in tumor development at many stages including 
initiation, promotion, malignant conversion, invasion 
and metastasis, it affects therapy response and immune 
surveillance. After infiltrating tumors, immune cells engage 
in a comprehensive and dynamic crosstalk with cancer cells. 
Researchers have revealed some of the molecular events that 
mediate this dialog.(4) The immune system can respond to 
cancer cells in two ways, either by reacting against tumor-
specific antigens (molecules that are unique to cancer cells), 
immunity to carcinogen-induced tumors in mice is directed 
into this antigens, or against tumor-associated antigens 
(molecules that are expressed differently by cancer cells and 
normal cells).(5,6)
 Gotten argumentative idea from immunosurveillance 
hypothesis, we supposed that the immune system could be 
harnessed to recognize malignant cells as foreign agents 
and eliminates them, this was now become available 
after our understanding about tumor immunity and have 
been improved with better techniques. In mouse models 
with  gene  deletion  to  eliminate  the  immune  effector 
mechanisms such as the type 1 interferons, the study showed 
that immune  system  clearly  reduced  the  incidence  of 
tumor.(7-11) Three outcomes were possible as the immune 
system encountered a nascent tumor, initiating a process 
termed as “immunoediting”(12); elimination of the cancer, 
cancer equilibrium, when there is immune selection of 
less  immunogenic  tumors  during an  antitumor  immune 
response (13); or tumor escape, which is the growth of 
tumor variants that resist immune destruction (12).
 In the past 25 years, progress in immunology guide 
to a new understanding and set a bridge of cellular and 
molecular interplays between the immune system and a 
Cancer is usually viewed as an evolutionary process that 
results from the accumulation of somatic mutations in the 
progeny of a normal cell which leads to a selective growth 
merit in the mutated cells and ultimately to uncontrolled 
proliferation.(15,16) Human cancer occurred most 
easily in epithelial tissues such as the skin, colon, breast, 
prostate or lung.(17) Cancer research has in latest decades 
characterized the cellular and molecular events that enable 
the malignant transformation of cells harboring oncogenic 
alterations. These events include uncontrolled proliferation; 
evasion of tumor suppression; inhibition of cell death; 
creation of a particular microenvironment containing blood 
vessels, stromal and immune cells; and the acquisition of 
invasive and metastatic potential.(1) Furthermore, our 
knowledge of oncogenes and tumor suppressor genes 
has been enriched by the development of next-generation 
sequencing techniques, which have identified a lot of 
genes which are mutated in different types of cancer.(18)
In other words, the ability to sustain chronic proliferation 
become the most fundamental character of cancer cells. 
Carefully, the normal tissues control the production and 
release of growth-promoting signals which instruct inlet 
into and progression via the cell growth- and-division cycle, 
therefrom insuring a homeostasis of cell number and so the 
maintenance of normal tissue architecture and function. 
Through these signals, cancer cells can regulate their own 
destinies. Largely, the enabling signal were transmitted by 
growth factor which bind cell-surface receptors, typically 
containing intracellular tyrosine kinase domains.(1)
 The proliferative signaling in cancer cells, are capable 
to sustain in many alternative ways, which are stimulating 
autocrine proliferative via the expression of cognate 
receptors, by producing growth factor ligands themselves, 
or stimulating normal cells within the supporting tumor-
associated stroma, which will repay with various growth 
factors for cancer cells.(19,20) Receptor signaling can also 
be deregulated by raising the levels of receptor proteins 
displayed at the cancer cell surface, rendering such cells 
hyper-responsive to otherwise-limiting numbers of growth 
factor ligand. The same outcome can result from structural 
changes in the receptor molecules which facilitate ligand-
independent firing. Many tumor suppressors which operate 
tumor, suggest the cancer research as a myriad phenotypic 
complexities and manifestations of a small set of underlying 
organizing principles.(14)
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of oncogenic signaling and subcritical shortening  of 
telomeres.(1)
 Identical to normal tissues, tumors need sustenance in 
the form of nutrients and oxygen and also  a capability to 
evacuate metabolic wastes and carbon dioxide. This could 
be utilized by angiogenesis process to generated tumor-
associated neovasculature. The angiogenic switch is ruled 
by countervailing factors comprised of signaling proteins 
which is bind to stimulatory or inhibitory cell-surface 
receptors showed by vascular endothelial cells, then induce 
or oppose the process.(25,26) The notable prototypes 
of angiogenesis inducers and inhibitors are vascular 
endothelial growth factor (VEGF)-A and thrombospondin 
(TSP)-1, respectively.(1)
 VEGF gene expression can be upregulated both by 
hypoxia and by oncogene signaling.(27-29) A developmental 
regulatory program, called as the ‘‘epithelial-mesenchymal 
transition’’ (EMT), has become prominent can obtain 
the capabilities to invade, to  resist  apoptosis,  and  to 
disseminate.(30-34) By co-opting a process involved in 
many different steps of embryonic morphogenesis and 
wound healing, carcinoma cells can concomitantly gain 
multiple attributes that enable invasion and metastasis. This 
multifaceted EMT program can be activated transiently 
or stably, and to differing degrees, by carcinoma cells 
throughtout the course of invasion and metastasistly 
implicated as a means by which transformed epithelial cells.
We have described the hallmarks of cancer as obtained 
functional capabilities which allow cancer cells to survive, 
proliferate and disseminate. These functions are obtained in 
different tumor types via distinct mechanisms and at various 
times during the course of multistep tumorigenesis. There 
are two enabling characteristics facilitating the acquisition. 
Most prominent is the development of genomic instability 
in cancer cell that generates random mutations including 
chromosomal rearrangement. Among these are the rare 
genetic alterations that can create hallmark capabilities. A 
second enabling characteristic involves the inflammatory 
state of premalignant and frankly malignant lesions which 
is driven by cells of the immune system, some of them 
are serving  to  promote  tumor  progression  via  various 
manners.(1)
 Another functionally important attribute of cancer 
cells development might therefore be added to the list 
of core hallmarks.(35-37) The first involves the major 
reprogramming of cellular energy metabolism to support 
continuous cell growth and proliferation, replacing the 
metabolic program that operates in most normal tissues and 
fuels the physiological operations of the associated cells. 
in various ways to confine cell growth and proliferation have 
been uncovered through their characteristic inactivation in 
one or another form of animal or human cancer.  Many 
of these genes have been validated as bonafide tumor 
suppressors by way of gain- or loss-of-function experiments 
in mice. The  retinoblastoma-associated (RB) and tumor 
protein (TP)53 proteins are encoded by two prototypical 
tumor suppressors. Those suppressors are operating as 
central control nodes within two key complementary 
cellular regulatory circuits which govern the decisions of 
cells to proliferate or, alternatively, activate senescence and 
apoptotic programs.(1) 
 Cancer cells with blemishes in RB pathway function 
are missing the services of a critical gatekeeper of cell-
cycle progression whose absence approves persistent 
cell proliferation. Over than last two decades, studies has 
established a natural barrier to cancer development known 
as programmed cell death (apoptosis).(20-22) Tumor cells 
unfold a variety of strategies to confine or circumvent 
apoptosis. The most common is loss of TP53 tumor 
suppressor function, which eliminates this critical damage 
sensor from the apoptosis-inducing circuitry. Other ways 
to attain this, tumors might downregulating proapoptotic 
factors (Bax, Bim, Puma), or by short-circuiting the extrinsic 
ligand-induced death pathway to increase expression of 
antiapoptotic regulators (C cell lymphoma (Bcl)-2, Bcl-xL) 
or of survival signals (insulin-like growth factor (IGF)-
1/2). The multiplicity of apoptosis-avoiding mechanisms 
presumably potrays the diversity of apoptosis-inducing 
signals which cancer cell populations encounter throughtout 
their evolution to the malignant state.(1,23)
 Probably more important, necrotic cell death releases 
proinflammatory signals into the surrounding tissue 
microenvironment, in contrast to apoptosis and autophagy, 
which do not. As consequence, necrotic cells can recruit 
inflammatory cells of the immune system (4,24) whose 
dedicated function is to survey the degree of tissue damage 
and repeal associated necrotic debris. In neoplasia, multiple 
lines of evidence show that immune inflammatory cells can 
be actively tumor promoting, knowing that such cells are 
capable of fostering angiogenesis, cancer cell proliferation 
and invasiveness. The two barriers to proliferation, 
senescence and crisis/apoptosis, have been rationalized as 
crucial anticancer defenses which are hard-wired into our 
cells, being deployed to impede the outgrowth of clones 
of preneoplastic and frankly neoplastic cells. Thus, cell 
senescence is arising conceptually as a protective barrier 
to neoplastic expansion which can be triggered by various 
proliferation-associated anomalies, including high levels 
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The second one involves active evasion by cancer cells 
from attack and elimination by immune cells, this ability 
highlights the dichotomous roles of an immune system that 
both antagonizes and enhances tumor development and 
progression. Both of these capabilities may well prove to 
facilitate the development and progression of many forms 
of human cancer and therefore can be considered to be 
emerging hallmarks of cancer (Figure 1).(1)
The Cancer Genome Landscapes
The Hallmarks of cancer
Figure 1. The hallmarks of cancer.(1) (Adapted with permission 
from Elsevier).
Most  cancers are driven by genomic changes which 
dysregulate key oncogenic pathways influencing cell 
growth and survival. Just now, we can exploit tumor 
genetic information for its full clinical potential. Over these 
past years, the convergence of discovery, technology and 
therapeutic development has eshtablished an unparalleled 
opportunity to examine the hypothesis that systematic 
knowledge of genomic information from individual tumors 
can improve clinical outcomes for many cancer patients.(3)
 Ten years ago, the idea that all genes changed in 
cancer could be identified at base-pair resolution would 
have seemed like science fiction. Now, such genome-wide 
analysis is routine, done by sequencing of the exome or of 
the whole genome. Compare to  more than $100,000 cost 
per case when first prototypical exomic studies of cancer 
evaluated about 20 tumors, now studies reporting the 
sequencing of more than 100 tumors of a given type are 
the norm with cost that has been reduced 100-fold.(38-40) 
Although vast amounts of data can now be readily obtained, 
deciphering this information in meaningful terms is still 
challenging.(2) 
 When do mutations occur? Studies in colorectal tumors 
told a story about a series of mutation over time, evolving 
the benign into malignant.(41,42) First mutation known as 
the “gatekeeping”, furnish the normal epithelial cell with 
selective growth advantage. The gatekeeping capable to 
outgrow surround cells to become a microscopic clone. 
Gatekeeping mutations in the colon most often happen in 
the adenomatous polyposis coli (APC) gene.(43) The small 
adenoma which results from this mutation grows slowly, 
but a second mutation in another gene, such as K-Ras, 
unleashes a second round of clonal growth which allows an 
expansion of cell number.(42) The cells with only the APC 
mutation may remain, but their cell ammounts are small 
compared with the cells that have mutations in both genes. 
The mutation process followed by clonal expansion. Genes 
mutations such as phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha (PIK3CA), Smad4 and 
TP53. In the end will generate a malignant tumor which can 
invade through the underlying basement membrane, and can 
metastasize to lymph node to reach a distant organs such as 
liver.(44)
 But, that huge complex information described 
about cancer genomes sometimes could be misleading. 
After all, even advanced tumors are not entirely out of 
control, as evidenced by the dramatic responses to agents 
that target mutant B-Raf in melanomas (45) or mutant 
anaplastic lymphoma kinase (ALK) in lung cancers (46). 
Apparently, even a single mutant gene interfering could 
stop cancer in its track, though just for a moment. This 
known as Albeit transient. The driver genes currently 
known to be classified into one or more of 12 pathways. 
The discovery of the molecular components of these 
pathways is one of the biggest achievements of biomedical 
research, a tribute to investigators working in fields which 
encompass biochemistry, cell biology and development, 
and also cancer. Based on core cellular processes, these 
pathways can be organized into cell fate, cell survival and 
genome maintenance. Many studies showed the opposing 
relationship between cell division and differentiation, as 
the arbiters of cell fate. Cell-autonomous alterations made 
cancer cells divide abnormally, such as those controlling 
cell fate, their surrounding stromal cells are absolutely 
normal and do not keep pace, but with abnormal vasculature 
of tumors which is asymmetry ramification. As opposed to 
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Figure 2. Genomic alterations affecting actionable signaling pathways in common solid tumors.(3) (Adapted with permission from 
American Society of Clinical Oncology).
the well-ordered network of arteries, veins, and lymphatics 
which control nutrient concentrations in normal tissues, 
the vascular system in cancers is tortuous and lacks 
uniformity of structure.(47,48) Surrounding with bizarre 
microenvirontment, cancer cells are toxically exposed 
by many substance, for example reactive oxygen species 
(ROS). Even without microenvironmental poisons, cells 
could have mistakes while replicating their DNA or during 
division (49,50), and checkpoints exist to either slow down 
such cells or make them commit suicide (apoptosis) under 
those circumstances (51-53).
 In past few years, a consilience of tumor biology, 
genomics technology, computational innovation and drug 
discovery has encouraged unprecedented advances in 
translational cancer research. This revolutionary scientific 
landscape has been punctuated by a growing amount of 
examples wherein the knowing of specific tumor genetic 
underpinnings has announced rational clinical deployment 
of targeted agents. When a driver genetic alteration (e.g., 
mutation which dysregulates a protein on which the cancer 
cell depends critically for viability) is effectively intercepted 
by a targeted small molecule or monoclonal antibody, 
impressive clinical responses may result. Genetic molecular 
framework raise a  promising results and overaching 
hypothesis for the cancer genome era, especially in non-
small-cell lung cancer and melanoma, which previously had 
been exemplified the limitation of empirical treatment. This 
hypothesis is undergirded by three main principles gleaned 
from over past a decade research performed over the past 
decade, described in detail as follows (3):
Principle 1 
Genetic alteration can enact the molecular pathways 
involved in tumor survival and progression. Somatic genetic 
derangement plays an important role in the genesis and 
maintenance of human cancers in majority. Tumorigenesis 
can also be promoted by germline mutations in important 
subsets of patients. The discovery of recurrent genomic 
alterations dramatically expanded the compendium of 
oncogenes and tumor suppressor genes while also offering 
crucial insights into specific cellular processes that become 
dysregulated in carcinogenesis, such as cell differentiation 
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Inflammation is classically regarded as a feature of innate 
immunity, which is different  from adaptive immunity by 
the receptors mediating its activation and its rapid onset. 
Innate immunity is also more evolutionarily ancient than 
adaptive immunity and is triggered by foreign microbial 
and viral structures, that known as pathogen-associated 
molecular patterns (PAMP), or normal cellular constituents 
released upon injury and cell death, called as damage-
(and arrest thereof), proliferation, apoptosis, tumor 
metabolism, and chromatin biology.(1) As illustrated in 
Figure 2, genomic changes that are druggable in principle 
take place in a substantial proportion of several major 
tumor types. Most of these tumors also contain additional 
mutations, which, even though not directly druggable 
themselves, might dysregulate down-stream effectors 
targeted by existing or developmental therapeutics. One 
widely cited example is lung adenocarcinoma, where at least 
60% of patients harbor driver oncogenic signaling pathway 
mutations.(54)  Breast cancer is noteworthy in this regard too. 
Majority of patients harbor driver changes (mutation or gene 
amplification) affecting genes such as the human epidermal 
growth factor receptor (HER)2 and fibroblast growth 
factor receptor (FGFR)1 tyrosine kinases, PIK3CA (which 
encodes a catalytic subunit of phosphoinositol-3 kinase 
(PI3K)),  or  Cyclin  D1  gene  (CCND1)  (which  encodes 
cyclin D, a cell-cycle protein that may render dependency 
on cyclin-dependent kinases (CDK) and sensitivity to CDK 
inhibitors).(55-58) Acute myeloid leukimia, brain tumors, 
and some other malignancies involve repetitive hotspot 
mutations in the isocitrate dehydrogenases 1 and 2.(39,59), 
enzymes that initially gained recognition for their roles in 
basic cellular metabolism (e.g., the tricarboxylic acid cycle). 
More recently, cancer-associated isocitrate dehydrogenase 
(IDH)1  and  IDH2 mutations  were  shown  to  generate 
an oncometabolite, known as 2-hydroxyglutarate (60,61), 
which regulates DNA (hyper)methylation (62,63), histone 
demethylation (64) and oxygen-sensing enzymes (65). 
Though specific tumorigenic mechanisms remain badly 
understood, the expanding recognition of epigenetic and 
metabolic pathways in tumor biology and progression 
has spawned new drug discovery attempts (66-69) that 
will likely influence future genomics-driven therapeutic 
directions.
Principle 2
Oncogenic pathways targeted anticancer agents, should have 
entered clinical trials. We have decade-long knowledge about 
how genomic alteration govern the tumorigenic mechanism, 
but still it was not enough as a basis to revolutionize the 
oncology treatment framework. The advances in cancer drug 
development witnessed unprecedentedly. A vast spectrum 
of therapeutics directed toward multiple effector proteins 
spanning most cancer signaling pathways has incorporated 
clinical trials and, in some cases, clinical practice. Regarding 
the latter, the National Cancer Institute in 2012 listed 19 
targeted therapeutics (including 15 signal transduction 
inhibitors and four targeted antiangiogenic drugs)  which 
had received regulatory approval in oncology.(70) This 
value, which does not include immunotherapy or antibody-
drug conjugates, competes the total number of targeted 
anticancer agents in the whole developmental pipeline 
just 8 years earlier.(71) Nearly 150 additional compounds 
are listed as clinical candidates in a public database (72), 
and dozens more proprietary compounds have entered 
development.
Principle 3
Tumor genomic profiling was now enable in the clinical 
arena, due to advances genomic technologies. This will 
support to deliver a targeted precision medicine therapeutic 
for patients. Subjects have to undergo a stratification based 
on their individual tumor genetic/molecular make up to find 
the salient cancer gene mutations especially for patients 
with advanced disease.
 Cancer is a disease of the genome. So it needs a 
constellation of genomic structure alteration to dictate 
their clinical behavior as the treatment response. Whereas 
explaining the nature and importance of these genomic 
changes has been the objective of cancer biologists for come 
decades, ongoing global genome characterization efforts 
are revolutionizing both tumor biology and also the optimal 
paradigm for cancer treatment at an unprecedented scope. 
The pace of advance has been empowered, in large part, 
through disruptive technological innovations which render 
complete cancer genome characterization feasible on a big 
scale.(73) 
 Determining a rational cancer therapeutic choice for 
better patients outcomes will be enabled with comprehensive 
genomic information available for oncology field. In the 
next decade cancer treatment will head to a genomics-
driven. The paradigm would be a complementary to other 
frameworks that shaping the development of oncology 
therapeutic, i.e immunotherapy, stem cell based therapy or 
tumor microenvironment targeting therapy (Figure 3).
Inflammation, Immunity and Cancer
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Figure 3. Schema of personalized medicine. A genome-based vision for personalized cancer medicine will require a paradigm shift 
in both diagnosis and treatment. Traditionally, tumors are classified by site of origin. In the future, tumor nucleic acid will be profiled 
for a wide array of genomic alterations with a view to specific, tailored treatment options for each individual patient.(73) (Adapted with 
permissiom from American Society of Clinical Oncology).
associated molecular patterns (DAMP). PAMPs and 
DAMPs can be recognized by pattern-recognition receptors 
(PRRs), whichever belong to the toll-like receptor (TLR) 
family.(73,74) Once activated, innate immunity results 
in upregulation of MHC class I and II and costimulatory 
molecules, a numerous inflammatory chemokines and 
cytokines which attract and prime T cells for activation 
through diverse antigen receptors.(75) While in adaptive 
immunity, T and B lymphocytes will be activated and further 
amplify the initial inflammatory response. So, type 1 helper 
T cells (Th1 cells) activate macrophages both through cell-
to-cell contact and interferon (IFN)-γ secretion, Th2 cells 
activate  eosinophils  via cytokine release, and B cells secrete 
antibodies that activate the complement cascade, as well as 
phagocytes, NK cells and mast cells, through Fc receptors.
(75-80) However, the inflammatory response could be put 
off by particular immune cells, especially Tregs (81).
 The presence of leukocytes within tumors, was 
observed back in the 1800s  by Rudolf Virchow, given the 
first indication of a possible link between inflammation 
and cancer. But it is only during the last decade that clear 
evidence has been obtained that inflammation has an 
important role in tumorigenesis, and some of the underlying 
molecular mechanisms have been elucidated.(83) A 
role for inflammation in tumorigenesis is now generally 
accepted, and it has become obvious that an inflammatory 
microenvironment is an essential component of all tumors, 
including some in which a direct causal relationship with 
inflammation is not yet proven.(84) The fact is, less than 10% 
of all cancers are caused by mutations in germline, mostly it 
was due to somatic mutations coupled with environmental 
factors (associated with chronic inflammation). Up to 20% 
of cancers related to chronic infections, 30% to tobacco 
smoking and inhaled pollutants (such as silica and asbestos), 
and 35% was related to dietary factors (20% of cancer 
burden is linked to obesity).(85)
 The link between inflammation and tumor development 
has been extensively recognized.(84) At precancerous stages, 
the presence of chronic inflammation in  an  organ helps 
promoting cancer outbreak and growth. The  inflammatory 
context may be the result of viral infection such as human 
papillomavirus (HPV) in cervical (86) and  head  and neck 
carcinoma (87) or hepatitis B virus (HBV) and hepatitis 
C virus (HCV) in hepatocellular carcinoma (88); external 
bacterial infections, such as Helicobacter pylori in gastric 
cancer (89) and non-Hodgkin gastric lymphoma (90) or 
the augmented permeability of the epithelial barrier to 
commensal microbiota promoting the development of 
colorectal cancer (CRC)(91); or the presence of noxious 
chemicals such as smoke for lung cancer (92) (Figure 
4). The inflammatory milieu can promote tumor growth 
through the production of cytokines such as interleukin (IL)-
6, IL-1 or tumor necrosis factor (TNF)-a (84), in addition 
to angiogenic molecules such as VEGF-A, transforming 
growth factor-b (TGF-b), adenosine, prostaglandin E2 (93) 
and suppressor myeloid or T cells attracting chemokines, 
including c-x-c motif ligand (CXCL)1, CXCL5, c-c motif 
ligand (CCL)2 and CCL12.(94,95) Indeed, preventive 
treatments with anti-inflammatory agents, such as aspirin 
or Cox-2 inhibitors have shown efficacy in decreasing the 
incidence of CRC.(96) More strikingly, the antibiotics 
cure of Helicobacter pylori infections and the vaccination 
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against HPV and HBV have significantly reduced the 
incidence of gastric cancer (97), cervical carcinoma (98) 
and hepatocellular cancer (99), respectively. Once a primary 
cancerous lesion is established, inflammatory cells can also 
act as tumor promoting elements. Accordingly, the density 
of tumor infiltrating macrophages or a colony stimulating 
factor (CSF)-1 response gene signature correlates with poor 
prognosis and metastasis in breast (100), lung (101), thyroid 
(102) and liver cancer (103). Moreover, it has been suggested 
that tumor-associated macrophages are implicated in the 
metastatic process in human breast cancer.(104)
 Even though it is now well known that the induction 
of inflammation by bacterial and viral infections raises 
cancer risk (106), new work has shown that in addition 
to being a tumor initiator by virtue of its high carcinogen 
content, tobacco smoke is also a tumor promoter because 
of its ability to trigger chronic inflammation (107). In 
the same way, obesity, with an alarming rate of growing 
number in prevalence, promotes tumorigenesis in the 
liver (108) and pancreas (109). Most solid malignancies 
show in older individuals, and even old age (110) and cell 
senescence (111) are postulated to be tumor promoters 
which act through inflammatory mechanisms. Along with 
its pro-tumorigenic effects, inflammation also influences 
the host immune response to tumors and can be used in 
cancer immunotherapy (112) and to augment the response 
to chemotherapy (113). Yet, in some cases, inflammation 
can diminish the beneficial effects of therapy.(4,114)
 Tumors grow within a tangled network of epithelial 
cells, vascular and lymphatic vessels, cytokines and 
chemokines, plus infiltrating immune cells. These infiltrated 
immune cells type will affect in tumor progression which 
can vary according to cancer type.(115) Indeed, immune 
infiltrates are heterogeneous between tumor types, and are 
very diverse from patient to patient. Many types of immune 
cell that might be found in a tumor, including macrophages, 
dendritic cells, mast cells, natural killer (NK) cells, naive 
and memory lymphocytes, B cells and effector T cells 
(including various subsets of T cell, those are T helper (Th) 
cells, Th 1 cells, Th2 cells, Th17 cells, regulatory T (T-Reg) 
cells, T follicular helper (TFH) cells and cytotoxic T cells). 
These immune cells can be located in the core (the centre) of 
the tumor, in the invasive margin or in the adjacent tertiary 
lymphoid structures (TLS). The analysis of the location, 
Figure 4. Major events and immune players in cancer natural history. A cartoon depiction of the development of a cancerous lesion 
in which the normal tissue is exposed to stress that leads to an influx of inflammatory cells, mainly from the innate immunity. If chronic 
inflammation continues, there are prominent changes in the infiltration that will then be characterized by M1 macrophages, Th1 and Th17 
cells and T effector (Teff) cell presence.(105) (Adapted with permission from Elsevier).
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Figure 5. Cells and chemokines that coordinate the tumor micro- environment.(115) (Adapted with permissiom from Macmillan 
Publishers Limited).
density and functional orientation of the different immune 
cell populations (which we have termed the ‘immune 
contexture’ (115) in large annotated collections of human 
tumors has allowed the identification of components of the 
immune contexture that are beneficial, as well as those that 
are deleterious, to patients. In addition, bioinformatics tools 
(116,117) have permitted the identification of chemokines 
and cytokines that are involved in shaping the immune 
contexture (Figure 5) (94).
 Tumor growth is assisted by tumor-associated 
macrophages (TAM), the major leukocyte population 
infiltrating cancers.(118) Although macrophages have the 
potential  to  attack  and  eliminate  tumor  cells, TAMs 
exhibit many protumoral features which are partly shared 
by  macrophages  involved  in  tissue  repair,  and  they 
interfere with the function and proliferation of immune 
effectors.(119) In many human tumors, a high number of 
TAMs associated with poor prognosis.(120) 
 Another cell used to monitor clinical outcome and 
response to therapy in human is myeloid-derived suppressor 
cells (MDSC), whereas the finding of high number of 
MDSCs shows a bad prognosis (121). MDSCs have a 
myeloid origin, heterogeneous cell composition, and can 
negatively regulate adaptive and innate immune responses 
to cancer.(122) As an outcome of these different forms 
of inflammation, the tumor microenvironment conceives 
innate immune cells (including macrophages, neutrophils, 
mast cells, MDSCs, dendritic cells and natural killer cells) 
and adaptive  immune  cells  (T  and  B  lymphocytes)  in 
addition to the cancer cells and their surrounding stroma 
(that consists of fibroblasts, endothelial cells, pericytes, 
and mesenchymal cells).(123) To control and shape tumors 
growth, these cells networking each other in autocrine and 
paracrine way, by producing cytokine and chemokine, as 
well as expressing many immune mediators and modulators 
and abundantly activate different cell types into various state 
in the tumor microenvironment. This will tip the balance 
between tumor-promoting inflammation or antitumor 
immunity.(9,124)
 Non-cell-autonomous regulation is important in 
tumorigenesis of cancer cells. To keep survive, cancer cells 
need to communicate with stromal cells by humoral factors 
such as VEGF, FGFs, and Wnt. Many studies recently 
showed that extracellular vesicles (EV) also have an 
important role in cell communication and the development 
of cancer. EVs contain small noncoding RNAs, including 
microRNAs (miRNAs), which is contribute in cancer cells 
malignancy.(125) 
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 Tumor-derived exosomes (TEX) are harbingers of 
tumor-induced immune suppression because they carry 
immunosuppressive molecules and factors which known 
to interfere with immune cell functions. By delivering 
suppressive cargos consisting of proteins similar to those 
in parent tumor cells to immune cells, TEX directly or 
indirectly affect the development, maturation, and antitumor 
activities of immune cells. TEX bring genomic DNA, 
mRNA, and miRNAs to immune cells, and reprogramming 
responder cells functions to boost tumor progression. 
Antitumor immunotherapies can be hampered with TEX 
that equipped with tumor-associated antigens. In tumor 
microenvironment, TEX may be associated in antitumor 
immunity down-regulation signaling pathways. Thus, TEX 
have a potency to be used as noninvasive biomarkers of 
tumor progression.(126)
 Lately, tumor  immunologists  and  practicing 
oncologists  have seen a dream come true with the 
clinical implementation and regulatory approval of cancer 
immunotherapies.(127) It was first proposed by Paul 
Ehrlich, 50 years after Virchow, that the immune system 
can fight tumors (128), a suggestion reiterated by the 
immunosurveillance hypothesis of Burnet and Thomas 
(129). These hypotheses are based on the idea that cancer-
associated genetic changes, along with aberrant quality-
control mechanisms and epigenetic reprogramming, result 
in expression of tumor-specific antigens (neoantigens) and 
tumor-associated antigens (TAAs), which are non-mutated 
proteins to which T cell tolerance is probably incomplete 
due to their restricted tissue expression pattern.(130) 
These antigens can activate antitumor immunity and under 
particular circumstances, may also induce rejection of 
early neoplasms, a concept known as immunosurveillance.
(130,131) Yet, the tumor-controlling ability of the immune 
system was not widely accepted until the successful 
development of immune checkpoint inhibitors which trigger 
tumor rejection by activating cytotoxic T lymphocytes 
(CTL).(132)   
 The mediators and cellular effectors of inflammation 
are important constituents of the local environment of 
tumors. In many cancer types, inflammatory conditions 
could be detect before a malignancy. Oppositely, an 
oncogenic change induces inflammatory microenvironment 
and promotes the tumors progression. Regardless of 
its origin, ‘smouldering’ inflammation in the tumor 
microenvironment has many tumor-promoting effects. It 
assists in the proliferation and survival of malignant cells, 
promotes angiogenesis and metastasis, subverts adaptive 
immune responses, and changes responses to hormones 
Nutrient Competition, Metabolic Reprogramming and Immunoediting of Cancer
The discovery in early 2000s that the immune system 
controls not only tumor quantity but also tumor quality 
(immunogenicity) prompted a major revision of the cancer 
immunosurveillance hypothesis.(7,11) The study showed 
that tumors in mice with lacked of intact immune system 
were more immunogenic (will then termed as “unedited”), 
compare to tumors derived from immunocompetent mice 
(termed as edited) The idea that the immune system not only 
protects the host against tumor formation but also shapes 
tumor immunogenicity as the basis of cancer immunoediting 
hypothesis, that stresses the dual host-protective and tumor-
promoting actions of immunity on developing tumors.(133)
 The last 15 years have seen a reemergence of interest 
in cancer immunosurveillance and a widening of this 
concept into one termed cancer immunoediting. Strong 
provocative experimental data in human cancer studies 
then suggested that immune system not only protects the 
host against development of primary non-viral cancers 
but also carves tumor immunogenicity. There are three 
phases in cancer immunoediting, those are elimination 
(cancer immunosurveillance), equilibrium and escape. The 
complete understanding of the immunobiology of cancer 
immunosurveillance and immunoediting will hopefully 
stimulate development of more effective immunotherapeutic 
approaches to control and/or eliminate human cancers 
(Figure 6).(134)
 The understanding of cancer immunoediting principles 
that involved the dual host-protective and tumor sculpting 
actions in cancer will set the basis for novel individualized 
cancer immunotherapies.(131) When oxygen is present, 
most differentiated cells use mitochondrial oxidative 
phosphorylation to create energy in the form of adenosine 
triphosphate (ATP) which can be used to sustain cellular 
processes. But when oxygen is abstent, such cells revert to 
much less efficient glycolysis as a means of ATP production. 
Cancer cells often utilize glycolysis despite the presence of 
oxygen (aerobic glycolysis or the ‘‘Warburg effect’’).(135) 
When less efficient at producing energy, it is considered 
that this form of metabolism supports the macromolecular 
and chemotherapeutic agents. Now we have untangled the 
molecular pathways of cancer-inflammation links, we hope 
in the future new target molecules could be identified to 
improve diagnosis and treatments.(84)
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Figure 6. The Three Phases of the Cancer Immunoediting Process.(134) (Adapted with permission from Cell Press)
requirements of cell growth and proliferation. Thus, the 
field has primarily focused on Warburg metabolism as an 
adaptation that confers intrinsic growth advantages to tumor 
cells themselves. However, cancer cells may consume 
nutrients, particularly glucose, in excess of their requirement 
to sustain proliferation and cell growth.(136) This increases 
the possibility that nutrient consumption plays additional 
roles to meeting the intrinsic bioenergetic and biosynthetic 
requirements of cancer cells.(137,138) Warburg show 
that metabolism provides tumor cells with a cell-extrinsic 
advantage, promoting depletion of extracellular glucose that 
renders tumor-infiltrating T cells dysfunctional.(139)
 Instead of manipulating tumor cell metabolism, 
Ho, et.al., suggests an alternate approach to improve 
T cell function by imitating nutrient availability within 
transferred T cells during adoptive cell therapy (ACT). 
Phosphoenolpyruvate Carboxykinase (PCK1) converts 
oxaloacetate into phosphoenolpyruvate (PEP). By 
overexpressing PCK1 in transferred T cells, the PEP 
levels were able to be artificially increased, restoring T 
cell antigen receptor (TCR)-induced Ca2+ flux and anti-
tumor T cell function  despite  the  presence  of  low 
environmental glucose levels within tumors. Blocking 
glucose metabolism during expansion of T cells for 
adoptive immunotherapy withholds effector differentiation 
and promotes differentiation of memory cells that mediate 
superior tumor clearance.(140) These findings provide 
striking examples of how modulating T cell metabolism can 
improve the outcome of adoptive cell therapy for cancer. 
Antigenic tumors need glucose to metabolically restrict T 
cells, and moisten  their  effector  function  to  allow  tumor 
progression. This resource imbalance can be corrected with 
checkpoint blockade therapy through a direct effect in the 
tumor cells (Figure 7).(138,141)
 Unfortunately, many tumors can escape not only 
the recognition by adaptive immune response but also 
the prime immune cells, makes the role of the immune 
system in tumor elimination to be ambiguous. The tumors 
escape through several mechanisms, including direct 
interference with the cells of the adaptive immune response 
and indirect immunosuppression by modifying the tumor 
microenvironment. Tumors can take advantage of a pH 
control system, via the upregulation of glycolysis and the 
consequent lowering of pH in the tumor microenvironment, 
already exploited by specific immune cell subpopulations, 
to obtain control of the immune system and ppress both 
cytotoxic and antigen-presenting cells. This is achieved 
through the direct competition of tumor cells with 
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Figure 7. T cell metabolic programs match functional demands. Resting T cells oxidize glucose-derived pyruvate, along with lipids and 
amino acids, to efficiently produce ATP/energy required for immune surveillance.(141) (Adapted with permission from Annual Reviews).
actively proliferating glycolytic immune cells for glucose 
and indirectly through the creation by the tumor of a 
microenvironment which interferes with maturation and 
activation of antigen-presenting cells and naive cytotoxic 
T cells. Immunosuppressive properties of an acidic 
microenvironment in the surrounding of the tumor can thus 
provide additional advantages for upregulation of glycolysis 
by tumor cells, proposing that the two emerging hallmarks 
of cancer changed glucose metabolism and immune 
suppression, are in fact fundamentally linked.(142)
 The complex immunologic tumor microenvironment 
in human cancers, or immune contexture, including the 
location, density, and functional orientation of infiltrating 
hematopoietic cells correlate with patients’ clinical 
outcome.(143) In most cases, good prognosis (progression-
free survival (PFS) and/or overall survival (OS)) correlated 
with a strong infiltration of memory CD8+ T cells and 
a Th1 orientation. Other parameters as well as immune 
cells, cytokines, chemokines and other factors also 
influence the generation of a clinically efficient immune 
microenvironment. All types of immune cells can be found 
in many different proportions and locations in tumors. They 
include myeloid cells, B cells and all subsets of T cells 
(115,143,144).
 The “immunoscore” is a scoring system which came 
from the immune contexture (114,145,146) and is a clinically 
useful prognostic marker (147) based on the enumeration of 
two lymphocyte populations (CD3 and CD8), in both the 
core of the tumor (CT) and in the invasive margin (IM) 
of tumors. The immunoscore gives a score ranging from 
immunoscore 0, in which low densities of both cell types 
are found in both regions, to immunoscore 4, in which 
high densities are found in both regions. Immunoscore 
classification was known to have a prognostic significance 
in all stage I, II and III patients with CRC that was superior 
to that of the American Joint Committee on Cancer/ Union 
for International Cancer Control (AJCC/UICC) TNM (T 
stage, N stage, and tumor differentiation) classification 
system.(148-149) Statistic data reports that tumor invasion 
was depended on the host’s immune reaction. The effector 
memory T cells ability to recall previously encountered 
antigens and traffic into tumors may give an advantage in 
long-term immunity to human cancer.(150,151) These days 
a clinical validation of the immunoscore with standardized 
procedures is needed to seize clinical applicability for 
individual patients with CRC and other cancers.(152,153) 
The immunoscore also provides a tool and targets for new 
therapeutic approaches, including immunotherapy (as lately 
illustrated in clinical trials boosting T cell responses with 
anti-cytotoxic T-lymphocte-associated antigen (CTLA)-4, 
anti-programmed cell death (PD)-1, and anti-programmed 
cell death ligand (PDL)-1.(153-156)Epithelial – Mesenchymal Transition and Metastasis
In spite of the new advances in the treatment of cancer, 
metastatic disease remains mostly incurable and the main 
cause of cancer-related deaths. Metastases are the final 
results of a multistage processes which includes local 
invasion by the primary tumor cells, intravasation into 
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the blood or lymphatic system, survival in circulation 
(hematogenous and/or lymphatic), arrest at a distant organ, 
extravasation, survival in a novel environment and metastatic 
colonization. Each of these steps depends on specific 
phenotypic features of the tumor cell, also interactions with 
the host microenvironment and the immune system.(157-
159) The advance therapy of human cancer, currently still 
not yet reached the fully treatment for metastatic disease. 
Metastatic sub-clones can raise either in the early or late 
stage of primary tumor development. We need a deeper 
understanding of the genetic evolution of metastatic disease 
and the biology of metastatic process to reveal different 
therapies for primary tumors and metastatic diseases.
 Tumor metastasis is the most common cause of cancer-
associated mortality. To give increase to the outgrowth of 
metastatic tumors in a new organ microenvironment, cancer 
cells havet to overcome various types of stresses and several 
rate-limiting steps.(160) During metastasis formation, most 
dispersed cancer cells were destroyed, but a small subset of 
those cells can survive and colonize in the new environment. 
Metastatic niches (specialized tumor microenvironment) 
are considered to be responsible in nurturing disseminated 
cancer cells from micrometastases to full macrometastases. 
Cancer stem cells (CSC) also shown to be linked directly 
in the metastatic process. Thus, identifying the confining 
factors which regulate the properties of CSCs and their 
colonization of metastatic niches is essential for developing 
strategies to treat patients with metastatic tumors. In a recent 
issue of Nature, Huelsken and colleagues give a novel 
insight into how signals from the metastatic niche affect 
CSC self-renewal and metastatic colonization.(161,162) 
Disseminated cancer cells need to find a supportive sites to 
reside their specific microenvironment or “niches” so the 
stem cells  can regulate the self-renewal potential and access 
to different notions. Various tissues could be in favors 
for stem cell niches including the intestinal epithelium, 
hematopoietic bone marrow, epidermis, and brain.(163-166) 
In primary tumors, cancer cells may interact with native 
stem cell niches, and the interactions will end as cancer cells 
leave the tumor. The metastasis-initiating differentiated 
thyroid cancer (DTC) survival and fitness will depend on 
specific components of the host environment that play the 
part of a niche for these cells.(167)
 Study performed by Malanchi, et al., demonstrated the 
crucial role of  the stromal periostin for metastatic colonization 
by regulating the interactions of breast cancer stem cells 
and their metastatic niche.(162) The transdifferentiation of 
epithelial cells into motile mesenchymal cells is integral in 
the development, wound healing and stem cell behavior, 
also in contributes pathologically to fibrosis and cancer 
progression. This switch in cell differentiation and behavior 
is mediated by key transcription factors, including Snail, 
zinc-finger E-box-binding (ZEB) and basic helix-loop-
helix transcription factors, the functions of which are finely 
regulated at the transcriptional, translational and post-
translational levels. The reprogramming of gene expression 
throughtout EMT, as well as non-transcriptional changes, 
are initiated and controlled by signaling pathways that 
respond to extracellular cues. Among these, TGF-β family 
signaling has a predominant role, however, the convergence 
of signaling pathways is essential for EMT.(168)
 Although it is clear that EMT is involved in metastatic 
events in cancer, its participation in other events may be 
also highly relevant to tumor progression. TGF-β can 
prevent the progression of incipient tumors and promote 
tumor invasion and evasion of immune surveillance at 
advanced stages (169), directing apoptosis or survival 
plus EMT in many cell contexts. When TGF-β acts on 
activated Ras-expressing mammary epithelial cells, EMT 
is favored and apoptosis is inhibited, and resistance to 
TGF-β-induced cell death was associated with hepatocytes 
undergoing EMT.(170) Similarly, several weeks study of 
breast tumor-derived  NMuMG  cells  exposure to TGF-β 
generates cells  that  escape  apoptosis  and performed a 
sustained EMT (171). This model offers the opportunity 
to investigate  the  long-term  effect of chronic TGF-β 
exposure during fibrosis in epithelial tissues and in cancer 
cells.(32) Tumors can escape from immune superintendence 
by inducing tolerance or utilize immunoediting to modify 
their phenotype.(172) a study observed tumor relapse in a 
Neu/HER2-inducible transgenic tumor model after removal 
of the inducer, indicating that tumors depend on continuous 
oncogenic signaling is needed for tumor survival. However, 
all animals had residual foci that finally developed more 
aggressive new tumors of the EMT type.(173) These two 
studies suggest that EMT may be involved in the acquisition 
of resistance to targeted therapies and that cells belonging to 
the foci of minimal residual disease acquired a mesenchymal 
phenotype.(32)
 Inflammation is known to be correlated with the 
cancer and fibrosis progression. Interestingly, recent studies 
point to the inflammation-induced EMT as critical to this 
connection.(174) In the tumor microenvironment and 
in course of organ fibrosis (such as occurs with kidney 
obstruction, diabetes, and glomerulonephritis) different 
mechanisms converge on the induction of nuclear factor 
kappa-B (NF-κB), which increase the expression of EMT 
inducers and Snail in particular both at the transcriptional 
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and translational levels.(175-177) Together, these data 
indicate that EMT may not only be necessary for primary 
carcinoma to invade and disseminate, but also that these 
pioneer invasive cells with both a mesenchymal and a stem 
cell-like phenotype can generate a differentiated epithelial-
like structure. This reversion to the differentiated phenotype 
through a process of MET is important for the formation of 
macrometastasis and thus to form the bulk of the secondary 
tumor mass. This hypothesis was previously formulated 
from an analysis of the progression of colon primary tumors 
and liver metastases, where it was proposed that cancer 
stem cells could acquire a mesenchymal phenotype, and 
thereby become migratory cancer stem cells that will form 
metastasis.(178)
Cancer Stem Cells
Cancer is a disease of genomic instability, evasion of 
immune cells, an adaptation of the tumor cells to the 
changing environment genetic heterogeneity which is 
caused by tumors and tumor microenvironmental factors 
forms the basis of aggressive behavior of some cancer cell 
populations. Several studies have identified a subset of 
cancer cells, designated as tumor-initiating cell or CSC, 
with the ability for self-renewal and differentiation into 
distinct cell lineages. Recently, the hypothesis has emerged, 
and earned great momentum, that tumors are hierarchically 
arranged, with CSC being the primary drivers of tumor 
growth for proliferation, resistance to chemotherapy, and 
metastasis.(180-182) A combination of flowcytometry and 
xenotransplantation techniques led to the identification of 
leukemia-initiating  cells  (cluster  of  differentiation  (CD)34+ 
CD38)  and breast cancer-initiating cells (CD44+ CD24-/lo) 
and provided scientific basis for the CSC hypothesis.(182-
184) 
 Tumor heterogeneity and plasticity naturally 
consequences in many drug resistance development, disease 
recurrence and metastasis, especially in cells that sensitive 
to therapy.(185) The hypothesis that tumors rise through 
sequential mutation and clonal selection has been proposed 
to be incompatible with a CSC model. Frankly, studies such 
as that of Jan, et al., have provided compelling evidence 
that both models are correct.(186) Even though mutations 
may occur  in  any  cell, those which occur in non-self-
renewing cell populations are extinguished through cellular 
senescence. CSC mutation may lead to these selective 
population clonal growth, causing further mutation, 
and keep continue to mutate and evolve even after full 
transformation. Thus, cancers can consist of more than one 
CSC clones.(179,187)
 The CSC hypothesis explains that there exists, within 
a tumor, a minority cell type which has the characteristics of 
stem cells, these cells can self-renew and can differentiate to 
mold all of the cell types which constitute the original tumor 
from a small number of cells.(188) It seems clear that, at 
least in hematopoetic (189) and some solid tumors including 
pancreatic (190), prostate (191), colon (163,192,193), breast 
(194,195), lung (196) and brain (197,198), a small subset of 
cells can be isolated which can self-renew and form well-
differentiated tumors identical to that of the patient’s tumor 
from which they arise. Nevertheless, the CSC hypothesis 
may not be true for all tumor types or for all of these cells 
all of the time.(199-202) In reality, it has been offered that 
stemness may be a dynamic state, which is a function of the 
cell’s interaction with environment.(203).
 The CSC model states that tumors are organized 
hierarchically with a subset of tumor cells at their apex, 
which possess self-renewal and multilineage differentiation 
potential.(188,204) This model therefore suggests that 
tumors are organized in a similar, albeit distorted, mannered 
as are their tissues of origin, and could potentially explain 
several phenomena that are currently incompletely 
understood.(205) According to the CSC model, minimal 
residual disease and tumor recurrence after treatment would 
be a result from remaining therapy-resistant CSC fraction, 
whereas metastatic potential would be a CSC-specific 
property. This hypothesis could be appealing, but more 
experimental evidences are needed.(206)
 The definition of CSCs as the only self-renewing 
tumor cells that capable of seeding a new tumor implies 
that CSCs are also responsible for initiation of metastases, 
a notion strengthened by the connection between CSCs and 
EMT (178,206-209) which is associated with metastatic 
behavior and poor prognosis (210). Transient and long-term 
quiescence (dormancy), are the constitutional attributes of 
adult stem cells.(211,212) On the basis of this premise, stem 
cells are often identified by their propensity to retain DNA 
labels much longer than their rapidly proliferating offspring. 
Dormancy might be the crucial mechanism for the CSCs 
resistance to anti-proliferative chemotherapy. Besides, if 
indeed CSC occur in a dormant state, this would explain 
the appearance of local recurrence or distant metastasis after 
long lag periods.(163)
 It is often proposed that CSCs are resistant to therapy 
in the similar way that normal stem cells are protected 
against insult. These protections include, for example, 
mechanisms such as quiescence, expression of ATP-binding 
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cassette (ABC) drug pumps.(213) Some groups have started 
to explore if CSCs are indeed more resistant to therapy 
than their progeny. For example, CD133-expressing glioma 
cells which were survive from ionizing radiation convicted 
to have better relative to CD133-tumor cells.(214) CD44hi 
CD24lo breast cancer CSCs appear intrinsically resistant to 
conventional chemotherapy (215) and ionizing radiation 
(216). Meanwhile chronic myeloid leukemia (CML) 
is sustained by leukemic stem cells that are relatively 
resistant to the drug Imatinib.(217,218) Nevertheless, the 
phenomenon of intrinsically therapy-resistant CSCs cannot 
be generalized, as for instance, the undifferentiated cells 
which drive testicular germ cell tumors are more sensitive to 
radiation or cisplatin therapy than their differentiated cellular 
progeny.(219) Tumor cells that escape therapy, however, 
may not be endowed with intrinsic therapy resistance. 
Rather, they may simply be the stochastic winners of the 
tumor cell-killing process. On the opposite, when intrinsic 
differences in the sensitivity of cancer cells to therapy do 
exist, these may also be determined genetically rather than 
by epigenetic differences.(220) antiapoptotic proteins and 
resistance to DNA damage.
 In summary, CSC hypothesis, supported by large 
numbers of evidences data, have a big role in cancer 
prevention and therapy implications, but we still need more 
clinical trials to demonstrate that this pathways could really 
work as a target for reducing cancer incidence and could 
improve patients outcome.(179)
Immunity, both innate and adaptive, play an important 
influence in cancer development, either by promoting or 
attenuating tumorigenesis, at the same time opposing the 
cancer therapies effect into resistances, suggesting the 
mechanisms was correlated with chronic inflammation. 
Furthermore, cancer development and malignant 
progression associated with the accumulation of genetic 
alterations and normal regulatory processes loss, leading 
to the expression induction of tumor-specific antigens 
and TAAs, which activate antitumor immune responses. 
Signals that trigger acute inflammatory reactions usually 
stimulate dendritic cell maturation and antigen presentation, 
but chronic inflammation can also be immunosuppressive. 
This antagonism between inflammation and immunity also 
influences the outcome of cancer treatment and needs to be 
considered when designing new therapeutic approaches. 
Besides cancer cells, tumors exhibit another dimension 
Conclusion
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